MAMohammed A. Alblowi

Mohammed A. Alblowi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammed A. Alblowi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Depression and Anxiety Among Individuals Receiving Incretin Mimetic Medications: A Saudi Cross-Sectional Study

    by Ali M. Bahathig, Ayedh H. Alghamdi, Mohammed A. Aljaffer, Mohammed A. Alblowi, Metib S. Alotaibi, Deena N. AlNouwaiser, Asma’A M. Alshehri, Abdullah M. Alhejji, Wejdan S. Alruwaili, Ghassan A. Abuseif, et al.

    Background: Depression and anxiety are prevalent mental health disorders that substantially impact quality of life. The association of incretin mimetics, including glucagon-like peptide-1 (GLP-1) receptor agonists, with symptoms of depression and anxiety remain underexplored in Saudi Arabia. This study was conducted to assess the association between GLP-1 receptor agonist use and symptoms of depression and anxiety and to identify related factors. Methods: A cross-sectional study using convenience sampling was conducted among adults (≥18 years) treated with GLP-1 receptor agonists at King Khalid University Hospital (KKUH) in Riyadh, Saudi Arabia. Data were collected using a questionnaire developed by the research team, in addition to the Arabic versions of the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7). Results: A total of 235 participants were included, of whom 48.5% used GLP-1 receptor agonists for both glycemic control and weight loss. Only 31.9% had undergone psychiatric evaluation prior to initiating therapy, and 14.9% had a diagnosed psychiatric disorder. The mean anxiety score (GAD-7) was 4.82 ± 5, and the mean depression score (PHQ-9) was 6.13 ± 4.95. Multivariable analysis showed that higher odds of more severe depression were associated with using diabetes medications for weight loss in addition to diabetes treatment, a history of psychiatric disorders, and holding a bachelor’s degree. Exercising for 101–150 min per week was associated with lower odds of depression. Regarding anxiety, participants who exercised 101–150 min per week had significantly lower odds of anxiety compared with those who did not exercise, while a history of psychiatric disorders was associated with higher odds of more severe anxiety. Conclusions: This study’s findings highlight the importance of integrating both routine psychiatric screening and follow-up into diabetes and obesity management to enhance both psychological well-being and metabolic outcomes. They also reflect the benefit of physical activity for mental health, emphasizing the need to encourage exercise among individuals with diabetes or obesity.

  • Open Access

    Effectiveness of a Culturally Adapted Cognitive Rehabilitation Program for Traumatic Brain Injury in Saudi Arabia: A Retrospective Pilot Study

    by Mohammed A. Alblowi, Wael Abusrrah, Saeed Alshahrani, Ahmad K. Alsomari, Aws Alhazmi

    Traumatic brain injury (TBI) is a significant public health concern in Saudi Arabia, where access to specialized neurorehabilitation remains limited, and most cognitive rehabilitation protocols are imported from Western contexts with limited cultural tailoring. TBI frequently results in long-term cognitive impairments, particularly in memory, attention, and executive function. Although cognitive rehabilitation has shown promise internationally, the efficacy of such interventions can vary across cultures, with emerging evidence suggesting that culturally adapted programs may improve engagement and adherence. This retrospective pilot study aimed to evaluate the preliminary effectiveness and feasibility of a culturally adapted cognitive rehabilitation program that integrates linguistically and socially familiar tools for Saudi patients with TBI, encouraging further research in this area. This retrospective, single-arm pilot study was conducted at King Saud University Medical City (KSUMC), Riyadh, Saudi Arabia, between January 2021 and December 2024. Adult patients ( N = 11) with a documented diagnosis of TBI completed a 6-month cognitive rehabilitation program targeting attention, memory, and executive function domains. The intervention incorporated culturally familiar tools, including the Shaula mobile application and the Baloot card game, to enhance engagement. Global cognitive function was assessed using the Arabic version of the Montreal Cognitive Assessment (MoCA) at baseline and 6 months post-intervention, to evaluate potential cognitive improvements. The mean MoCA score improved from 18.36 [standard deviation (SD) = 5.57] at baseline to 22.63 (SD = 5.24) post-intervention. The mean difference of 4.27 points (SD = 4.49) on the raw MoCA scale represented a statistically significant within-participant improvement [ t (10) = 3.15, P = 0.010]. Males showed a larger mean improvement than females; however, this gender difference was not statistically significant ( P = 0.31 under the equal-variance assumption; P = 0.08 under the unequal-variance assumption) and should be interpreted cautiously given the minimal female subgroup ( n = 2). This retrospective, single-arm pilot study with a small sample size ( N = 11) and no control group provides preliminary evidence that a culturally adapted cognitive rehabilitation program may be associated with improved cognitive outcomes in Saudi patients with TBI. Embedding cognitive training within familiar Arabic-language digital exercises and a traditional card game suggests the program is feasible and acceptable in this context. These findings support the potential for such interventions to enhance engagement and adherence. However, larger prospective controlled trials with extended follow-up are necessary to confirm these initial results, clarify the specific contribution of cultural adaptation, and inform the development of context-appropriate neurorehabilitation services in the region.

  • Open Access

    Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug

    by Mohammed A. Alblowi, Fahad D. Alosaimi

    Tardive dyskinesia (TD) is one of the most serious and disturbing side-effects of dopamine receptor antagonists. It affects 20-50% of patients on long-term antipsychotic therapy. The pathophysiology of TD remains poorly understood, and treatment is often challenging. Here, we present a 32-year-old woman presenting with a 9-month history of TD occurring after risperidone withdrawal, and characterized almost exclusively by tongue protrusion. After being seen by different specialties and undergoing multiple investigations, she was eventually correctly diagnosed with TD by a specialist team and successfully treated with amantadine. Vigilance and awareness of this condition and its risk factors are required to make the correct diagnosis, especially in cases with unusual presentations caused by atypical antipsychotics, and treatment can be challenging.